BD company Wikipedia
This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
- 1940 BD launched the first sterilization technology for devices.
- 2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process.
- “Jack” Howe joins BD and becomes integral to developing sterility control procedures and refining the process for manufacturing disposable syringes and needles.
- 2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution.
- Quality of care, cost efficiency, healthcare worker and patient safety and experience
They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations. The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Embecta Corporation is a standalone public company focused on diabetes খেলাঘর বেড care.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
We know that possibilities are endless when people feel supported and inspired. Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. At BD, we believe that people are at the heart of every breakthrough, solution, and step forward.
1948 BD founders turn over the company to their sons. 1956 BD enters the Brazilian syringe market and quickly becomes the largest provider in the country with two modern plants and HQ in Sao Paulo. 1955 BD begins using AMI of France to manufacture steel tubes for hypodermic needles. 1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.
Sign up to get the latest company news, events, and future opportunities straight to your inbox. At BD, your ideas, curiosity and purpose can makea global impact In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients. Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America.